Corvus Q4 Net Loss Widens on R&D Investment; Positive Clinical Data, Cash Runway Secured to 2028
CRVS has more than doubled off its 52-week low of $2.54 on light trading volume (0.3× avg).
Summary
Corvus Pharmaceuticals reported a Q4 net loss of $12.32 million, or $0.15 per share, which widened due to higher research and development costs for its clinical trials. However, the company also announced positive Phase 1 safety and efficacy data for soquelitinib in atopic dermatitis. This financial update comes shortly after Corvus completed a $189 million public offering, securing its cash runway into Q2 2028, as previously disclosed in an 8-K filing. The market will likely balance the increased R&D spend and wider loss with the promising clinical progress and robust liquidity.
At the time of this announcement, CRVS was trading at $15.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.54 to $26.95. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.